These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Peripheral blood stem cell mobilization in multiple myeloma patients treat in the novel therapy-era with plerixafor and G-CSF has superior efficacy but significantly higher costs compared to mobilization with low-dose cyclophosphamide and G-CSF. Chaudhary L; Awan F; Cumpston A; Leadmon S; Watkins K; Tse W; Craig M; Hamadani M J Clin Apher; 2013 Oct; 28(5):359-67. PubMed ID: 23765597 [TBL] [Abstract][Full Text] [Related]
7. Low-Dose Cyclophosphamide versus Intermediate-High-Dose Cyclophosphamide versus Granulocyte Colony-Stimulating Factor Alone for Stem Cell Mobilization in Multiple Myeloma in the Era of Novel Agents: A Multicenter Retrospective Study. Zannetti BA; Saraceni F; Cellini C; Fabbri E; Monaco F; Guarini A; Laszlo D; Martino M; Olivieri A; Imola M; Tosi P; Chiarucci M; Zuffa E; Lanza F Transplant Cell Ther; 2021 Mar; 27(3):244.e1-244.e8. PubMed ID: 33781522 [TBL] [Abstract][Full Text] [Related]
8. [Comparison of Plerixafor or Cyclophosphamide Combined with G-CSF in Mobilization of Peripheral Blood Stem Cells in Multiple Myeloma]. Li WT; Ma LM; Lian Y; Wang QG; Gao ZJ; Zhao S Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Oct; 31(5):1403-1409. PubMed ID: 37846691 [TBL] [Abstract][Full Text] [Related]
9. Plerixafor for autologous peripheral blood stem cell mobilization in patients previously treated with fludarabine or lenalidomide. Malard F; Kröger N; Gabriel IH; Hübel K; Apperley JF; Basak GW; Douglas KW; Geraldes C; Jaksic O; Koristek Z; Lanza F; Lemoli R; Mikala G; Selleslag D; Worel N; Mohty M; Duarte RF Biol Blood Marrow Transplant; 2012 Feb; 18(2):314-7. PubMed ID: 22001752 [TBL] [Abstract][Full Text] [Related]
10. Cost and clinical analysis of autologous hematopoietic stem cell mobilization with G-CSF and plerixafor compared to G-CSF and cyclophosphamide. Shaughnessy P; Islas-Ohlmayer M; Murphy J; Hougham M; MacPherson J; Winkler K; Silva M; Steinberg M; Matous J; Selvey S; Maris M; McSweeney PA Biol Blood Marrow Transplant; 2011 May; 17(5):729-36. PubMed ID: 20813198 [TBL] [Abstract][Full Text] [Related]
11. [Efficiency and safety analysis of Plerixafor combined with granulocyte colony-stimulating factor on autologous hematopoietic stem cell mobilization in lymphoma]. Ji MM; Shen YG; Gong JC; Tang W; Xu XQ; Zheng Z; Chen SY; He Y; Zheng X; Zhao LD; Zhao WL; Wu W Zhonghua Xue Ye Xue Za Zhi; 2023 Feb; 44(2):112-117. PubMed ID: 36948864 [No Abstract] [Full Text] [Related]
12. Chemotherapy-based versus chemotherapy-free stem cell mobilization (± plerixafor) in multiple myeloma patients: an Italian cost-effectiveness analysis. Lazzaro C; Castagna L; Lanza F; Laszlo D; Milone G; Pierelli L; Saccardi R Bone Marrow Transplant; 2021 Aug; 56(8):1876-1887. PubMed ID: 33753907 [TBL] [Abstract][Full Text] [Related]
13. Additional plerixafor to granulocyte colony-stimulating factors for haematopoietic stem cell mobilisation for autologous transplantation in people with malignant lymphoma or multiple myeloma. Hartmann T; Hübel K; Monsef I; Engert A; Skoetz N Cochrane Database Syst Rev; 2015 Oct; 2015(10):CD010615. PubMed ID: 26484982 [TBL] [Abstract][Full Text] [Related]
14. Stem Cell Mobilization for Multiple Myeloma Patients Receiving Daratumumab-Based Induction Therapy: A Real- World Experience. Thurlapati A; Roubal K; Davis JA; Shah SZ; Smith D; McGann M; Gaffney K; Cendagorta A; Maldonado A; Weeda E; Hashmi H Transplant Cell Ther; 2023 May; 29(5):340.e1-340.e4. PubMed ID: 36804934 [TBL] [Abstract][Full Text] [Related]
15. Are we choosing mobilization regimens for autologous stem cell transplantation in multiple myeloma wisely: A single center comparison of GCSF+/-plerixafor vs cyclophosphamide/GCSF+/-plerixafor. Yang C; Dehghani M; Hopman W; Bhella S J Clin Apher; 2022 Aug; 37(4):348-353. PubMed ID: 35218068 [TBL] [Abstract][Full Text] [Related]
16. Beyond CD34+ cell dose: impact of method of peripheral blood hematopoietic stem cell mobilization (granulocyte-colony-stimulating factor [G-CSF], G-CSF plus plerixafor, or cyclophosphamide G-CSF/granulocyte-macrophage [GM]-CSF) on number of colony-forming unit-GM, engraftment, and Day +100 hematopoietic graft function. Alexander ET; Towery JA; Miller AN; Kramer C; Hogan KR; Squires JE; Stuart RK; Costa LJ Transfusion; 2011 Sep; 51(9):1995-2000. PubMed ID: 21392017 [TBL] [Abstract][Full Text] [Related]
17. The CXCR4 and adhesion molecule expression of CD34+ hematopoietic cells mobilized by "on-demand" addition of plerixafor to granulocyte-colony-stimulating factor. Girbl T; Lunzer V; Greil R; Namberger K; Hartmann TN Transfusion; 2014 Sep; 54(9):2325-35. PubMed ID: 24673458 [TBL] [Abstract][Full Text] [Related]
18. Safety and efficacy of upfront plerixafor + G-CSF versus placebo + G-CSF for mobilization of CD34(+) hematopoietic progenitor cells in patients ≥60 and <60 years of age with non-Hodgkin's lymphoma or multiple myeloma. Micallef IN; Stiff PJ; Stadtmauer EA; Bolwell BJ; Nademanee AP; Maziarz RT; Partisano AM; Marulkar S; DiPersio JF Am J Hematol; 2013 Dec; 88(12):1017-23. PubMed ID: 23907769 [TBL] [Abstract][Full Text] [Related]
19. Cyclophosphamide plus granulocyte-colony stimulating factor for hematopoietic stem cell mobilization in patients with multiple myeloma. Lin TL; Wang PN; Kuo MC; Hung YH; Chang H; Tang TC J Clin Apher; 2016 Oct; 31(5):423-8. PubMed ID: 26340986 [TBL] [Abstract][Full Text] [Related]
20. Phase I/II Study of Intravenous Plerixafor Added to a Mobilization Regimen of Granulocyte Colony-Stimulating Factor in Lymphoma Patients Undergoing Autologous Stem Cell Collection. Cashen AF; Rettig M; Gao F; Smith A; Abboud C; Stockerl-Goldstein K; Vij R; Uy G; Westervelt P; DiPersio J Biol Blood Marrow Transplant; 2017 Aug; 23(8):1282-1289. PubMed ID: 28476490 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]